Fig. 3 | Scientific Reports

Fig. 3

From: Metabolomic reprogramming of the tumor microenvironment by dual arginase inhibitor OATD-02 boosts anticancer immunity

Fig. 3

Pharmacodynamic effects of OATD-02 in CT26 tumor-bearing mice. (A) Experimental design: Mice (n = 3) were treated with OATD-02 (100 mg/kg PO, BID), and blood and tumor samples were collected at 2 h and 16 h after the last dose. (B) LC-MS/MS analysis of the serum concentrations of OATD-02 (left) and L-arginine (right) at the indicated time points. (C) Representative MALDI-MSI ion images of L-arginine, proline, spermine, and spermidine levels in tumors of untreated and OATD-02-treated mice (n = 2) at 2 h and 16 h after the last dose.

Back to article page